Journal article
Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells
LH Porter, K Hashimoto, MG Lawrence, C Pezaro, D Clouston, H Wang, M Papargiris, H Thorne, J Li, A Ryan, S Norden, D Moon, DM Bolton, S Sengupta, M Frydenberg, DG Murphy, GP Risbridger, RA Taylor
BJU International | WILEY | Published : 2018
DOI: 10.1111/bju.14043
Abstract
Objective: To determine the relevance of intraductal carcinoma of the prostate (IDC-P) in advanced prostate cancer by first examining whether IDC-P was originally present in patients who later developed advanced prostate cancer and then using patient-derived xenografts (PDXs) to investigate the response of IDC-P to androgen deprivation therapy (ADT). Materials and Methods: We conducted a retrospective pathology review of IDC-P in primary prostate biopsy or surgery specimens from 38 men who subsequently developed advanced prostate cancer. Overall survival was calculated using the Kaplan–Meier method. To demonstrate the response of IDC-P to ADT, we established PDXs from seven patients with fam..
View full abstractGrants
Awarded by Victorian Cancer Agency
Funding Acknowledgements
We thank the Australian Prostate Cancer BioResource for specimen collection and the patients who donated their tissue. We also thank Stephen Plymate for providing the AR-V7 antibody. This work was supported by funding from the National Health and Medical Research Council of Australia (Fellowship to M.G.L. 1035721, Fellowship to G.P.R. 1102752, Project Grant 1077799), the Victorian Cancer Agency (Fellowship to R.A.T. MCRF15023, CAPTIV Program), the EJ Whitten Foundation, the Peter and Lyndy White Foundation and TissuPath Pathology.